MBK stands firm on offer price for AsiaPharm

The private equity company has no plans to raise its S$0.725 per share offer for the Chinese pharmaceutical firm, but reserves the right to revise the offer price if a competitive situation arises.


Quick Poll

How will you alter your portfolio after the US election result?





« View results

Previous polls ››

Underweight US
  17%
 
Overweight US
  42%
 
Underweight EMs
  6%
 
Raise cash levels
  20%
 
No change
  15%
TOTAL VOTES: 144
Comment on this

« Back

Previous polls ››

December 2016/January 2017 Magazine
AsianInvestor Magazine